Relative Drug Pricing Is Bad Medicine

Tackling High Drug Prices Requires Patent Reforms, Too - R Street Institute

President Donald J. Trump just released his second executive order (EO) addressing high prescription drug prices. This is perhaps a welcome announcement for those who have to pay for prescription drugs on a regular basis. U.S. drug prices remain nearly three times higher than in other countries leaving many Americans struggling to afford their prescribed medications. However,... The post Tackling High Drug Prices Requires Patent Reforms, Too app…

Relative Drug Pricing is Bad Medicine

On May 12, President Trump signed an Executive Order aimed at lowering US prescription drug prices. In keeping with his tariff policy, the president was motivated by the price differences — often vast — between identical prescription drugs sold in the US and in the rest of the world. The EO ordered the US Trade Representative and the Secretary of Commerce to take action against countries that were “free-riding on American pharmaceutical innovati…

The New Healthcare Reality Under the Trump Administration

Jeffrey Casberg, M.S., of IPD Analytics and Luke Greenwalt, MBA, of IQVIA, both members of the Managed Healthcare Executive (MHE) editorial advisory board, will provide a midyear assessment of the pharmacy market and the policy and politics affecting it. Topics to be discussed include the possibility of tariffs, the most-favored nation drug pricing executive order, aspect of the reconciliation bill that could affect the pharmaceutical and pharma…

MFN EO Raises A Range of Potential Options for DTC Implementation

On May 12, President Trump signed an Executive Order (EO) that directs drug manufacturers to reduce US drug prices to align with those paid in economically comparable countries, a concept known as most favored nation (MFN) pricing. The EO outlines a series of near-term steps the federal government may take to make manufacturers lower their US drug prices. One of these steps is implementing a direct-to-consumer (DTC) purchasing program to enable …

Health agencies to set price targets as part of Trump’s executive order to slash U.S. drug prices

President Trump signed an executive order implementing a Most-Favored-Nation pricing model to align U.S. drug costs with the lowest global prices. The policy targets brand-name drugs without competition, potentially saving $88 billion over seven years and ending “foreign freeriding” on U.S. innovation. Pharmaceutical companies must... Continue reading...

Executive order on drug costs: what employers need to know

President Donald Trump has issued an executive order (EO) aimed at reducing prescription drug prices by aligning them with those of other wealthy nations.